94 completed. 94 Phase 2, 17 Phase 3, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 94 | Completed 94 |
| Phase 3 | 17 | Completed 17 |
| Phase 1 | 8 | Completed 8 |
Follow Deglutition Disorders: new trials by email Literature Review of Deglutition Disorders trials Research Report on Deglutition Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alginate vs Sucralfate for GERD Symptomatic Relief Alginate, Sucralfate - GERD | Phase 2 / Phase 3 | Completed | CMH Lahore Medical College and Institute of Dentistry | 140 | 2025-04-01 | 2026-07-15 |
| Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD MHS-1031, Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Microbiome Health Sciences | 255 | 2023-03-03 | 2026-07-27 |
| A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old Dexlansoprazole - Gastroesophageal Reflux Disease (GERD) | Phase 2 | Completed | Takeda | 71 | 2023-02-20 | 2026-07-29 |
| Magnesium for Peroral Endoscopic Myotomy Magnesium sulfate, Normal Saline - Esophageal Spasm | Phase 2 | Completed | Stanford University | 92 | 2020-12-28 | 2024-05-21 |
| Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis X842, X842 Placebo, Lansoprazole - Reflux Esophagitis | Phase 2 | Completed | Jiangsu Sinorda Biomedicine Co., Ltd | 90 | 2020-01-21 | 2025-07-17 |
| Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease JP-1366, JP-1366 placebo, Esomeprazole 40mg - GERD | Phase 2 | Completed | Onconic Therapeutics Inc. | 188 | 2019-11-15 | 2022-07-13 |
| A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients Calcium (13C)Carbonate, Gastric acid inhibitors, Gastric pH monitoring - Gastroesophageal Reflux Disease | Phase 2 | Completed | Otsuka Pharmaceutical Co., Ltd. | 55 | 2017-10-31 | 2019-04-01 |
| Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study Prucalopride - Ineffective Esophageal Motility, Dysphagia | Phase 2 | Completed | University of Calgary | 28 | 2017-10-20 | 2020-03-25 |
| The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus Alginates - Barretts Esophagus With Dysplasia | Phase 2 | Completed | Medical University of South Carolina | 24 | 2017-08-25 | 2023-03-08 |
| Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) APT-1011, Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | Adare Pharmaceuticals, Inc. | 106 | 2017-06-22 | 2023-04-26 |
| Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial EMST, smTAP - Parkinson's Disease, Dysphagia | Phase 2 | Completed | Teachers College, Columbia University | 65 | 2016-09-01 | 2023-12-22 |
| Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI) Vonoprazan, Esomeprazole, Esomeprazole Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Takeda | 256 | 2016-07-14 | 2020-02-18 |
| Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants Alginate-antacid group, Non antacid alginate group - Gastroesophageal Reflux Disease, Acid Reflux | Phase 2 / Phase 3 | Completed | Universiti Sains Malaysia | 24 | 2016-07-01 | 2018-05-04 |
| A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) IW-3718, Matching Placebo, PPI - Gastroesophageal Reflux Disease | Phase 2 | Completed | Ironwood Pharmaceuticals, Inc. | 282 | 2016-03-01 | 2019-10-15 |
| VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease Parts A/B: Adrabetadex, Parts A/B: Sham Control - Niemann-Pick Disease, Type C | Phase 2 / Phase 3 | Completed | Mandos LLC | 56 | 2015-10-01 | 2023-02-22 |
| Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors IW-3718, Matching Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Ironwood Pharmaceuticals, Inc. | 93 | 2014-02-01 | 2016-08-01 |
| Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER) Lansoprazole, Placebo - Premature Infants, Gastroesophageal Reflux | Phase 1 / Phase 2 | Completed | Seoul National University Hospital | 12 | 2013-09-01 | 2014-11-19 |
| Botulinum Toxin Injection in Hypercontractile Esophagus Esophageal endoscopic injection of botulinum toxin, No injection of botulinum toxin - Nutcracker Oesophagus | Phase 2 | Completed | Hospices Civils de Lyon | 24 | 2013-08-01 | 2025-12-19 |
| YF476 in Barrett's Esophagus YF476, YF476 placebo - Barrett's Esophagus | Phase 2 | Completed | Trio Medicines Ltd. | 27 | 2013-05-15 | 2021-04-12 |
| Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis CJ-12420, Esomeprazole - Erosive Esophagitis, GERD | Phase 2 | Completed | HK inno.N Corporation | 206 | 2013-05-01 | 2014-08-08 |
Showing 20 of 94. Sign in to see all of them.
Gastroesophageal Reflux (54) · Heartburn (11) · Stroke (10) · Esophagitis (5) · Eosinophilic Esophagitis (4) · Esophageal Achalasia (3) · Head and Neck Neoplasms (3) · Pain (3) · Parkinson Disease (3) · Asthma (2) · Barrett Esophagus (2) · Carcinoma, Non-Small-Cell Lung (2) · Cough (2) · Dyspepsia (2)
Digestive System Diseases (93) · Esophageal Diseases (93) · Gastrointestinal Diseases (92) · Esophageal Motility Disorders (62) · Otorhinolaryngologic Diseases (32) · Pharyngeal Diseases (32) · Pathological Conditions, Signs and Symptoms (23) · Signs and Symptoms (21) · Nervous System Diseases (15) · Brain Diseases (13) · Central Nervous System Diseases (13) · Signs and Symptoms, Digestive (13) · Cardiovascular Diseases (10) · Cerebrovascular Disorders (10)
Esomeprazole (10) · Rabeprazole (7) · lesogaberan (5) · Lansoprazole (4) · Dexlansoprazole (3) · Omeprazole (3) · Sugars (3) · Alginates (2) · YF 476 (2) · arbaclofen placarbil (2) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · 2-Hydroxypropyl-beta-cyclodextrin (1) · APT-1011 (1) · AZD1386 (1) · AZD2066 (1)
AstraZeneca (10) · Takeda (5) · Hospital de Mataró (3) · US Department of Veterans Affairs (3) · University of Florida (3) · Addex Pharma S.A. (2) · Assistance Publique - Hôpitaux de Paris (2) · Eisai Inc. (2) · Ironwood Pharmaceuticals, Inc. (2) · Mayo Clinic (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Seoul National University Hospital (2) · University of Arkansas (2) · University of Utah (2) · XenoPort, Inc. (2)
United States (49) · France (9) · Canada (8) · Belgium (7) · Germany (7) · Poland (6) · South Korea (5) · United Kingdom (5) · Australia (4) · Brazil (4) · Hungary (4) · Italy (4) · Mexico (4) · Netherlands (4) · Spain (4)
Debra Silberg, MD (2) · Giselle Carnaby-Mann, PhD (2) · Han-Suk Kim, MD, PhD (2) · Jay Huff, M.D. (2) · Marie Sundin (2) · Yufang Lu (2) · Akbar Fotouhi, MD, PhD (1) · Alessandro Repici, MD (1) · Alexandre Jacinto, MD (1) · Amy Foxx-Orenstein, D.O. (1) · Arash Etemadi, MD, PhD (1)
PMID 16137276, PMID 16361020, PMID 17270511, PMID 17602265, PMID 17721405, PMID 20110554, PMID 20132154, PMID 20176418, PMID 20451523, PMID 20955603, PMID 21320138, PMID 21402616, PMID 21441148, PMID 22111863, PMID 22206777, PMID 22730470, PMID 23318482, PMID 23320520, PMID 23721547, PMID 23782628, PMID 23831596, PMID 23919738, PMID 24533896, PMID 25027286, PMID 25304129, PMID 25407279, PMID 25409838, PMID 25498307, PMID 25693609, PMID 25726315, PMID 27130637, PMID 27712711, PMID 28916953, PMID 30740545, PMID 30974039, PMID 31977454, PMID 32092310, PMID 32343001, PMID 33782049, PMID 35181572, PMID 36345090, PMID 38401078, PMID 39836012, PMID 40525490
2008 (3), 2015 (2), 2016 (1), R03DC004942 (1), R21HD054752 (1), R21HD055677 (1)